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Abstract 38 
In this work a step forward in investigating the use of prescription drugs, namely erectile 39 
dysfunction products, at European level was taken by applying the wastewater-based 40 
epidemiology approach. 24-h composite samples of untreated wastewater were collected at the 41 
entrance of eight wastewater treatment plants serving the catchment within the cities of Bristol, 42 
Brussels, Castellón, Copenhagen, Milan, Oslo, Utrecht and Zurich. A validated analytical 43 
procedure with direct injection of filtered aliquots by liquid chromatography-tandem mass 44 
spectrometry was applied. The target list included the three active pharmaceutical ingredients 45 
(sildenafil, tadalafil and vardenafil) together with (bio)transformation products and other 46 
analogues. Only sildenafil and its two human urinary metabolites desmethyl- and 47 
desethylsildenafil were detected in the samples with concentrations reaching 60 ng L-1. The 48 
concentrations were transformed into normalized measured loads and the estimated actual 49 
consumption of sildenafil was back-calculated from these loads. In addition, national 50 
prescription data from five countries was gathered in the form of the number of prescribed daily 51 
doses and transformed into predicted loads for comparison. This comparison resulted in the 52 
evidence of a different spatial trend across Europe. In Utrecht and Brussels, prescription data 53 
could only partly explain the total amount found in wastewater; whereas in Bristol, the 54 
comparison was in agreement; and in Milan and Oslo a lower amount was found in wastewater 55 
than expected from the prescription data. This study illustrates the potential of wastewater-56 
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based epidemiology to investigate the use of counterfeit medication and rogue online pharmacy 57 
sales. 58 
 59 
Keywords: erectile dysfunction; prescription drugs; LC-MS/MS; consumption; counterfeit; 60 
wastewater-based epidemiology 61 
 62 
Highlights: 63 
o Wastewater-based epidemiology approach expanded to investigate counterfeit 64 
medication 65 
o Very sensitive analytical method allowed identification of target analytes at low ng L-1 66 
level 67 
o Different spatial trends in sildenafil use were found across Europe 68 
 69 
1. Introduction 70 
The chemical analysis of raw wastewater with advanced mass spectrometry techniques allows 71 
for the determination of human urinary biomarkers when these are excreted in sufficient 72 
concentrations and remain stable on their way along the sewer system (Castiglioni et al., 73 
2013).The finding of specific biomarkers may reveal valuable near real-time information 74 
regarding a population’s lifestyle, illness and exposure to external agents. Successful studies 75 
thus far have revealed the population’s level of oxidative stress (Y. Ryu et al., 2016), its 76 
exposure to pesticides (Rousis et al., 2017), and to phthalate plasticizers (González-Mariño et 77 
al., 2017), its consumption of legal substances such as alcohol, nicotine or caffeine (Baz-Lomba 78 
et al., 2016; Gracia-Lor et al., 2017; Yeonsuk Ryu et al., 2016), its use of illicit drugs 79 
(Causanilles et al., 2017a, 2017c; Ort et al., 2014) and other psychoactive substances (Bade et 80 
al., 2017; Castrignanò et al., 2017; Causanilles et al., 2017b; González-Mariño et al., 2016), 81 
and its intake of certain pharmaceuticals (Causanilles et al., 2016). 82 
The monitoring of active pharmaceutical ingredients (APIs) and their metabolites in wastewater 83 
offers an interesting value (van Nuijs et al., 2015) because these substances have gone through 84 
clinical trials before their final usage approval. Therefore, the information regarding the 85 
absorbed dose after drug intake, the biotransformation pathway and the excretion profile and 86 
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rates in biological matrices is relatively well known (Abed, 2014). This information facilitates 87 
the selection of the appropriate target urinary biomarker in the application of wastewater-based 88 
epidemiology (WBE). Concentrations of the unchanged product and/or its metabolites in 89 
untreated wastewater, considered a collective, diluted pooled urine sample, can be converted 90 
into measured mass loads (ML) and then back-calculated into actual consumption estimates 91 
applying the appropriate correction factor. In addition, the number of dispensed pharmaceutical 92 
in the form of defined daily doses (DDD) or product quantities dispensed by pharmacies or 93 
doctors can also be obtained (in most cases, depending on the pharmaceutical and the country 94 
legislation). From these data, the average amount of the API that has been legally dispensed per 95 
day can be calculated and transformed into predicted loads (PL) (Carballa et al., 2008; Verlicchi 96 
et al., 2014). 97 
The comparison between the actual consumption derived from ML and PL from prescription 98 
data can result in three different scenarios:  99 
(i) Consumption estimated from measured wastewater loads is lower than the load 100 
expected from the dispensed data. This would represent the case of pharmaceuticals 101 
under consumption, with a lower usage that the quantity prescribed or defined by 102 
the DDD;  103 
(ii) Consumption estimated from measured wastewater loads is similar to the expected 104 
from dispensed data, which represents the ideal situation, where there is no misuse;  105 
(iii) Consumption estimated from measured wastewater loads is higher than the load 106 
expected from the dispensed data; 107 
This third scenario represents the case of pharmaceuticals that are genuine but available from 108 
parallel import or in a counterfeit or falsified form and that can be acquired from other sources 109 
such as rogue online pharmacies or black market. This was the case observed for the 110 
phosphodiesterase type V (PDE5) inhibitor sildenafil, API in erectile dysfunction 111 
pharmaceuticals, in a study performed in the Netherlands in 2013 (Venhuis et al., 2014a). 112 
Results showed that only one third to one half of the consumption estimated from wastewater 113 
loads could be related to the acquisition of the drug from legal sources (Venhuis et al., 2014a). 114 
However, the comparison needs to be handled with care, since other sources for discrepancy 115 
can be present. They might be related to the sewer system, with the incomplete release to the 116 
sewer system or elimination processes between the consumption point and the wastewater 117 
treatment plant (WWTP), namely  (bio)transformation, sorption and sedimentation (McCall et 118 
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al., 2016; Ramin et al., 2017, 2016; van Nuijs et al., 2015; Verlicchi et al., 2014). Alternatively, 119 
they could be related to other sources such as inaccurate or highly variable pharmacokinetic 120 
parameters between individuals, different applied dosages of the used API (which makes it 121 
difficult to compare it with a DDD), or no representative comparison (e.g. 1-week wastewater 122 
monitoring vs. monthly/yearly prescription data; national vs. local comparison). 123 
Erectile dysfunction is estimated to affect 25 to 35 million men over the age of 18 in Europe, 124 
according to the European Federation of Pharmaceutical Industries and Associations (EFPIA, 125 
2017). It is a disorder of increasing concern since an aging population will result in higher 126 
prevalence. Despite the high number of men affected, it is still highly stigmatized, and users 127 
usually tend to hide their related drug use. Illegal trading with products from the internet and 128 
with counterfeit medicines is increasing (Chiang et al., 2017). However, the individuals 129 
purchasing medicines via the internet are for the most part not sufficiently aware of the risks 130 
they run in doing so (Keizers et al., 2016). Concerns about the quality of these products may 131 
arise, specially towards the possible presence of impurities that may lead to poisoning if toxic, 132 
and an increased risk of side effects or overdosing. 133 
In this work the WBE approach was applied to assess the use of PDE5 inhibitors in eight 134 
European cities accounting for almost 5 million inhabitant equivalents. 24-h composite influent 135 
wastewater samples were collected in each city for seven consecutive days and analysed by 136 
liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Measured 137 
concentrations in the samples were converted into mass loads and back calculated with known 138 
pharmacokinetic information to estimate consumption. In addition, available data at national 139 
level of the number of prescribed or dispensed erectile dysfunction pharmaceuticals were 140 
gathered to discuss their correlation. 141 
 142 
2. Materials and methods 143 
2.1.Chemicals and materials 144 
The following analytes were selected in the study: sildenafil citrate, desmethylsildenafil, 145 
desethylsildenafil and noracetildenafil, purchased from LGC (Luckenwalde, Germany); 146 
vardenafil dihydrochloride, n-desethyl vardenafil, tadalafil, aminotadalafil, chloropretadalafil 147 
and n-octyl nortadalafil, purchased from TRC Toronto Research Chemicals Inc. (Ontario, 148 
Canada). Two isotopically labelled internal standards (ILIS) were used as surrogates: sildenafil-149 
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d8 and desmethylsildenafil-d8, supplied by TLC Pharmachem (Ontario, Canada). All the above-150 
mentioned standards were of high purity grade (>98%). Individual stock and working solutions 151 
were prepared in methanol and stored at -20 °C. Calibration curve was prepared daily by 152 
diluting with ultrapure water to a final composition water:methanol (90:10, v/v). 153 
Methanol and acetonitrile HPLC grade solvents were supplied by Avantor Performance 154 
Materials B.V (Deventer, the Netherlands). Formic acid (50% in water) was obtained from 155 
Fluka Analytical (Sigma-Aldrich, Stenheim, Germany). The ultrapure water was obtained by 156 
purifying demineralized water in an Elga Purelab Chorus ultrapure water system (High 157 
Wycombe, United Kingdom). Regenerated cellulose filters RC 0.2 µm were purchased from 158 
Phenomenex (Torrance, USA). 159 
2.2.Sample collection 160 
A week-monitoring sampling campaign was performed in March 2015 in eight European cities. 161 
For seven consecutive days 24-h influent composite samples were collected at the entrance of 162 
the WWTPs serving the cities of Bristol, England; Brussels, Belgium; Castellón, Spain; 163 
Copenhagen, Denmark; Milan, Italy; Oslo, Norway; Utrecht, the Netherlands; and Zurich, 164 
Switzerland. The number of inhabitants included in the total catchment area under study 165 
represented almost 5 million people in Europe. Table SI-1 compiles detailed information about 166 
the sample collection at the different locations: date of sample collection, influent flow (m3 day-167 
1), sampling mode and frequency, average wastewater temperature (°C), pH, biological and 168 
chemical oxygen demand (BOD5 and COD), total phosphate (Ptot), and nitrogen content as 169 
Kjeldahl (Ntot) and ammonia (NH4-N). 170 
2.3.Analytical methodology  171 
The analytical methodology used to perform the wastewater chemical analysis was previously 172 
validated (Causanilles et al., 2016). All samples were collected in high-density polyethylene 173 
bottles, shipped frozen to KWR in Nieuwegein (NL) and stored in the dark at –20 °C until 174 
treatment. Samples were thawed and homogenized. Then a 10 mL aliquot was spiked with 175 
deuterated analogues to act as surrogate and filtered with regenerated cellulose syringe filters 176 
(0,2 µm). With no further pre-treatment, a 100 µL aliquot of each sample was injected into the 177 
liquid chromatography coupled to triple quadruple mass spectrometer (Thermo Scientific TSQ 178 
Vantage, Thermo Electron, Bremen, Germany). Chromatographic separation was achieved with 179 
a XBridge C18 column (150 mm × 2.1 mm I.D., particle size 3.5 µm, Waters, Etten-Leur, the 180 
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Netherlands) preceded by a KrudKatcher ULTRA HPLC in-line SS filter (0.5 µm × 0.1 mm 181 
I.D., Phenomenex, Torrance, USA). The mobile phase consisted of an optimized water-182 
methanol-acetonitrile gradient at 0.3 mL min-1 flow. The MS system operated in selected 183 
reaction monitoring (SRM) and positive ionisation mode during data acquisition. For each 184 
compound two transitions of the precursor ion [M+H]+ were monitored, one for quantification 185 
and the second for confirmation purposes. Analyte concentrations were quantified using 186 
calibration with standards in solvent and the correspondent deuterated analogue. Additional 187 
details of the analytical method can be found in the Supplementary information: Table SI-2 188 
presents the specific LC-MS/MS parameters for compound identification, Table SI-3 p shows 189 
the quality parameters of the method’s performance, and Figure SI-1 presents an illustrative 190 
chromatogram of a standard mixture of the selected PDE5. 191 
2.4.Calculations 192 
The quantitative chemical analysis of the wastewater samples included in the study resulted in 193 
the concentrations of each analyte expressed in ng L-1. The daily mass loads were subsequently 194 
obtained by multiplying the measured concentration in each sample by the daily influent flow 195 
rate at the WWTP in m3 day-1. Loads, expressed as mg day-1, were normalized dividing them 196 
by the population included in the catchment area.  197 
Normalized loads were expressed as mg day-1 per 1000 inhabitants, allowing in this way the 198 
direct comparison of results among the different communities included in the study. In the case 199 
of concentration values in real sample below limits of quantification (LOQ), values were 200 
replaced by 0.5 × LOQ when at least one day in the week had a concentration value above the 201 
LOQ. Concentration values below limits of detection (LOD), as well as concentration values 202 
lower than LOQ when all values at that location were below LOQ, were set to 0.5 × LOD (Ort 203 
et al., 2014). Sildenafil actual consumption was estimated from measured ML as indicated 204 
elsewhere (Venhuis et al., 2014b) by summing the load of unchanged sildenafil and the 205 
absorbed dose back calculated from the metabolite load using the formula: [(Load 206 
desmethylsildenafil (moles) + desethylsildenafil (moles)) / 0,27]*474, and were expressed in 207 
mg week-1 1000 inh-1. The calculation was based on the available pharmacokinetic data and the 208 
assumption that there were no elimination processes such as (bio)transformation or sorption 209 
between the consumption point to the WWTP or dumping of unused drugs.  Further research 210 
of the biomarkers’ behaviour in the sewer (see the introduction) would be required to verify 211 
this assumption. Earlier stability studies confirmed there was not a statistically significant 212 
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decrease in concentration of the target compounds after 48 h storage at 4 °C (Causanilles et al., 213 
2016). 214 
PDE5 inhibitors are the API in pharmaceutical products used to treat erectile dysfunction (ED) 215 
and as pulmonary vasodilator antihypertensive (VA). Their classification within the ATC-216 
system (Anatomic Therapeutic Chemical) corresponds to the group of genitourinary system and 217 
sex hormones (G), urological (04B), erectile dysfunction (E). The individual codes are 218 
necessary to find the national prescription and sales data of all formulations containing them as 219 
API despite the differences in brand name. The codes of the three approved substances included 220 
in the study and their established DDDs can be found in Table 1. DDD is defined as the assumed 221 
average maintenance dose per day for a drug used for its main indication in adults (WHO, 222 
2017). Sildenafil does not only have a registration as erectile stimulant, but also for pulmonary 223 
arterial hypertension. For this treatment purpose, both the DDD and the number of prescriptions 224 
is lower. In the case of Belgium, only the prescription data for the application of sildenafil as 225 
VA was available. A similar trend in the prescription data was expected compared to the 226 
neighbouring country of the Netherlands and therefore the ratio ED/VA was extrapolated to 227 
estimate the number of prescriptions of sildenafil as erectile dysfunction drug in Belgium. 228 
The number of DDDs prescribed in the year 2015 in each country (see Table 1) was multiplied 229 
by the DDD value, in mg, and divided by the country’s population to normalize to 1000 230 
inhabitants, and 52 weeks in a year (van Nuijs et al., 2015). In this way, PLs were estimated, 231 
expressed in mg week-1 1000 inh-1. Next, the ratio PL/ML was calculated to enable the 232 
comparison between prescription-derived data and actual consumption from wastewater loads 233 
(Verlicchi et al., 2014). Statistical analysis of the data, using ANOVA to compare differences 234 
between cities and between weekdays and weekends was performed using GraphPad Prism 5. 235 
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Table 1. Information on the investigated pharmaceuticals and national prescription data. 236 
Pharmaceutical ATC code 
DDDa value 
(use) 
Total number of DDDs prescribed in 2015 
Belgium1 England2 Italy3 the Netherlands4 Norway5 
Sildenafil G04BE03 50 mg (ED)  
20 mg (VA) 
602,596b 
(ED) 
106,648 (VA) 
23,572,110 (ED) 
198,800 (VA) 
13,314,239 
(ED+VA) 
2,190,688 (ED) 
387,710 (VA) 
1,949,770 
(ED+VA) 
Tadalafil G04BE08 10 mg (ED) 85,276 9,120,725 13,314,239 1,570,918 2,203,956 
Vardenafil G04BE09 10 mg (ED) n.a. 1,262,350 n.a. 159,520 338,096 
VA: Vasodilator Antihypertensive 237 
ED: Erectile Dysfunction 238 
n.a.: not available 239 
a defined by the WHO Collaborating Centre for Drug Statistics Methodology, www.whocc.no 240 
b Estimated from the ED/VA ratio observed in the Netherlands 241 
Information source indicated with numbered superscript: 242 
 1 National Institute for Health and Disability Insurance, www.riziv.be 243 
2 National Health Service, www.nhsbsa.nhs.uk 244 
3 Agenzia Italiana del Farmaco, www.agenziafarmaco.gov.it 245 
4 Dutch Foundation for Pharmaceutical Statistics, www.sfk.nl 246 
5 The Norwegian Institute of Public Health, www.norpd.no 247 
 248 
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3. Results and discussion 249 
3.1.Measured concentrations  250 
Results from the week-monitoring sampling campaign are reported in Table 2, together with 251 
the LODs and LOQs. Measured concentrations per city are presented as the 7-day mean with 252 
standard deviation, expressed in ng L-1. Sildenafil and its two human metabolites were present 253 
at levels above the LOD in all cities and could be quantified in most of the samples. The parent 254 
compound was detected at a level between LOD and LOQ in the samples from Castellón and 255 
Milan, while in the city of Oslo it was at about the LOQ level only in the Sunday sample. When 256 
sildenafil was quantifiable, its concentrations were in the range of 4 to 19 ng L-1. 257 
Desmethylsildenafil, the less abundant sildenafil metabolite, could not be quantified in the cities 258 
of Castellón, Milan, Oslo and Zurich. In Copenhagen and Utrecht on 2 and 4 days, respectively, 259 
levels were <LOQ, and these were therefore replaced by 0.5 × LOQ for the calculation of the 260 
city’s average. Values were found in the range of 14 to 36 ng L-1. Desethylsildenafil, the most 261 
abundant metabolite of sildenafil, was quantified in all samples, with concentrations between 5 262 
and 51 ng L-1. Neither the other two APIs included in the study, tadalafil and vardenafil, nor 263 
their metabolites nor analogues were found above their LOD.  264 
The metabolite to parent concentration ratio was calculated when available. The ratio of 265 
desethylsildenafil to sildenafil ranged from 1.7 to 3.6 (6 cities, 2.8 ± 0.8). These results were in 266 
line with the range of ratios observed in the Dutch cities of Amsterdam, Eindhoven and Utrecht 267 
in the years 2013 to 2015 (Causanilles et al., 2016). The ratio of desmethylsildenafil to sildenafil 268 
ranged from 0.9 to 2.3 (4 cities, 1.6 ± 0.6). These results confirm literature findings: a lower 269 
ratio is expected for desmethylsildenafil, since it is the less abundant urinary metabolite 270 
(Muirhead et al., 2002). 271 
 272 
 273 
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Table 2. Measured concentrations (MCs) expressed in ng L-1 with standard deviation (± SD) for 7 sampling days, n=7. 274 
Compounds LOD, ng L-1 LOQ, ng L-1 MC (mean ± SD), ng L-1 
Bristol Brussels Castellón Copenhagen Milan Oslo Utrecht Zurich 
Sildenafil 2 6 12 ± 4 19 ± 3 (<LOQ) 14 ± 5 (<LOQ) 4 ± 2a 15 ± 4 9 ± 2 
Desmethylsildenafil 5 18 26 ± 7 36 ± 2 (<LOQ) 19 ± 8a (<LOQ) (<LOQ) 14 ± 4a (<LOQ) 
Desethylsildenafil 1 2 28 ± 8 33 ± 5 13 ± 3 51 ± 7 5 ± 1 8 ± 4 51 ± 4 32 ± 5 
Noracetildenafil 6 20 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
Tadalafil 2 8 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
Aminotadalafil 2 6 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
Chloropretadalafil 4 13 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
N-octylnortadalafil 30 100 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
Vardenafil 7 24 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
N-desethylvardenafil 9 30 (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) (<LOD) 
a At least one value out of 7 is >LOQ; then the values <LOQ are replaced by 0.5 × LOQ  275 
 276 
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3.2.Daily loads and actual consumption 277 
Measured concentrations were translated into normalized loads in mg day-1 per 1000 inhabitants 278 
to allow a better comparison between the cities included in the study. The 7-day average data 279 
for each city together with standard deviation is presented in Table 3. The highest normalized 280 
sildenafil load was found in the city of Brussels closely followed by Zurich and Copenhagen. 281 
Compared to these cities, a medium load was found in Bristol and Utrecht, and the lowest levels 282 
were observed in Milan and Castellón. For the metabolites a similar trend was found, in 283 
accordance with their excretion ratios. The daily variations are presented in Fig. 1, expressed 284 
as percentages of the total load. No statistically significant increase in loads was found in 285 
weekend samples compared to weekday samples, suggesting the use of sildenafil as needed and 286 
not with a clear recreational aim. The “weekend effect” is however very typical for some illicit 287 
drugs such as cocaine or ecstasy (MDMA) (Bijlsma et al., 2014; Causanilles et al., 2017c; 288 
Salvatore et al., 2015). Interestingly, in the case of sildenafil, the highest load is detected on 289 
Sunday whereas for the two metabolites the maximum is detected on Monday (Fig. 1). This 290 
could be explained by the metabolites being excreted later in time than the unchanged parent. 291 
Considering the MLs for sildenafil and its two metabolites, it was possible to back-calculate 292 
into actual sildenafil consumption by the population connected to the studied sewer system. 293 
This estimation was done as explained elsewhere (Venhuis et al., 2014b). The estimated 294 
consumption of sildenafil, in mg week-1 1000 inh-1, back-calculated from wastewater loads (see 295 
Table 3) arranged the cities in the following order from a higher to a lower estimated use 296 
(including previously published results from other Dutch cities (Causanilles et al., 2016): 1st 297 
Amsterdam, with 872 mg week-1 1000 inh-1; 2nd Copenhagen; 3rd Brussels; 4th Zurich; 5th 298 
Eindhoven, 432 mg week-1 1000 inh-1; 6th Bristol; 7th Utrecht; 8th Oslo; 9th Castellón; and 10th 299 
Milan.  300 
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Table 3. Averaged normalized loads for sildenafil and its two metabolites with standard deviations (± SD) for 7 consecutive sampling days. 301 
Sildenafil actual consumption estimated from ML, and PL calculated from prescription data.  302 
 
Loads (mean ± SD), mg day-1 1000 inh-1 
 
Bristol Brussels Castellón Copenhagen Milan Oslo Utrecht Zurich 
Sildenafil 2.8 ± 1.1 5.1 ± 1.0 0.2 ± 0.1 b 3.8 ± 1.2 0.4 ± 0.1 b 1.7 ± 0.7 a 2.4 ± 0.7 4.2 ± 1.5 
Desmethylsildenafil 6.2 ± 1.7 9.4 ± 1.3 0.6 ± 0.1 b 5.3 ± 1.9 a 1.0 ± 0.2 b 1.2 ± 0.1 b 2.1 ± 0.9 a 1.1 ± 0.2 b 
Desethylsildenafil 6.6 ± 2.1 8.5 ± 1.2 3.0 ± 0.6 13.7 ± 1.7 2.1 ± 0.5 3.7 ± 1.5 8.0 ± 0.5 13.9 ± 3.1 
Sildenafil actual consumption, 
ML (mg week-1 1000 inh-1) 
365 517 100 542 87 145 292 439 
Sildenafil predicted consumption, 
PL (mg week-1 1000 inh-1) 
415 55 n.a. n.a. 211 361 133 n.a. 
a At least one value out of 7 is >LOQ then when <LOQ replaced by 0.5 × LOQ  303 
b All values <LOQ then replaced by 0.5 × LOD (SD was obtained from the different daily flow rate) 304 
n.a. not available  305 
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 306 
Fig. 1. Daily variations expressed as the percentage of the total load, combining results for the 8 cities. The box represents the median, 25% and 307 
75% percentile values and the error bars extend to the minimum and maximum values. The coloured lines represent each of the cities. 308 
 309 
Page 15 of 23 
 
3.3.Comparison between predicted and measured loads 310 
The predicted loads (PLs) for the unchanged API sildenafil and its two urinary metabolites 311 
desmethyl- and desethylsildenafil are presented in Table 3 (the yearly prescribed mg are shown 312 
in Table SI-4). The highest PL was found for Bristol, followed by Oslo, Milan and Utrecht 313 
with similar values, and the lowest was for Brussels. PL were not calculated for tadalafil and 314 
vardenafil, since the literature indicates that only a minor amount of the unchanged form was 315 
putatively identified in urine. This would result in an expected concentration close to zero, 316 
which would be below the LOD in wastewater for this compound.  317 
Only in the case of Brussels (where the prescription data was estimated by extrapolating the 318 
Dutch trend) and Utrecht, the actual sildenafil consumption estimated from wastewater-based 319 
approach was higher than the expected by the national prescription data (see Table 3). Thus, in 320 
Brussels the PL of sildenafil was much lower than the actual ML in wastewater. This difference 321 
might be due to unregistered use of sildenafil (case (iii), see introduction), but one should bear 322 
in mind that, in this particular case, for the calculation of PL the estimation of prescribed DDDs 323 
was obtained by extrapolation from the Dutch ED/VA trend, because actual DDD data were 324 
lacking. The actual ED/VA ratio for Belgium may be different of course. Another possible 325 
reason for obtaining relatively low PLs, e.g. heavy rainfall during the sampling week, was 326 
discarded, as it did not occur. The second observation that can be made corresponds to the three 327 
cities, Bristol, Milan and Oslo, where PL/ML ratios for sildenafil were much higher than in 328 
Brussels and Utrecht. This translates into MLs lower than PL estimated from national 329 
prescription data. This could be explained by the non-consumption of the total prescribed 330 
amount, or by any of the other sources of discrepancy mentioned in the introduction such as a 331 
higher (bio)transformation or sorption of the compounds in the local sewer systems, or a less 332 
representative comparison between local and national prescription data. We currently do not 333 
have evidence to substantiate the likeliness of higher rates of in-sewer degradation in these 334 
countries. Overall, the comparison results must be handled with care since this study was 335 
performed only in one city per country in a limited time period (7 consecutive days), and 336 
therefore the extrapolation of results to the whole country’s prescription data will be surely 337 
biased by the specific spatial and temporal profiles of that city (versus other areas within the 338 
countries). 339 
In the cities of Amsterdam and Eindhoven, previously reported results (Causanilles et al., 2016) 340 
showed an even higher consumption, that could not be explained by national sales data (at least 341 
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60% of the wastewater loads of sildenafil were not explained by legitimately prescribed 342 
sildenafil (Venhuis et al., 2014a)). In Bristol, the predicted and measured values were in good 343 
agreement, while in Milan and Oslo the estimated consumption from wastewater was lower 344 
than the expected from prescription data. The final evaluation of the correlation between 345 
wastewater data and prescription data was found to be non-significant by Spearman’s 346 
correlation coefficient (ρ = -0.30) with p-value above 0.05 (p = 0.68) (see Fig. 2). 347 
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Fig. 2. Relationship between the predicted loads (PL) of sildenafil, calculated from the 350 
prescription data (DDDs), and actual sildenafil consumption estimated from the measured 351 
loads (ML) in wastewater (WW), both expressed in mg week-1 1000 inh-1. For Castellón, 352 
Copenhagen and Zurich, no prescription data were available. 353 
  354 
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4. Conclusions 355 
The present study is the first to compare the use of the erectile dysfunction products in different 356 
European cities through chemical analysis of wastewater. The analysis of influents revealed the 357 
presence of sildenafil and its two human metabolites in all cities sampled with average loads 358 
varying between 0.2 and 14 mg day-1 1000 inh-1. None of the other ED products analysed were 359 
observed in concentrations above the method detection limits. While it is known that sildenafil 360 
is available in products from illegal sources such as internet shops, the results of the present 361 
study show that consumption beyond prescribed doses is not common across Europe. Despite 362 
the limitations related to the assessment of both predicted and measured loads, it seems that the 363 
populations in Utrecht (and also in other cities in The Netherlands) and in Brussels might be 364 
more inclined towards the use of products from illegal sources or rogue online pharmacies than 365 
in the other three European cities included in the study for which prescription data were 366 
available (Bristol, Milan and Oslo). After this first study illustrating the potential of wastewater-367 
based epidemiology in this field, further research will allow to improve the application of this 368 
approach for investigating the use of rogue pharmacies and counterfeit medication.  369 
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Table SI-1. WWTPs characteristics. 
City Bristol Brussels Castellon Copenhagen Milan Oslo Utrecht Zurich 
Residential Population 886650 953987 180690 531000 1100000 580639 300000 410000 
Date of sample collection day 1 dd.mm.yyyy 16-3-2015 18-3-2015 25-3-2015 10-3-2015 10-3-2015 11-03-2015 4-3-2015 18-3-2015 
Date of sample collection day 2 dd.mm.yyyy 10-3-2015 19-3-2015 26-3-2015 11-3-2015 11-3-2015 12-03-2015 5-3-2015 19-3-2015 
Date of sample collection day 3 dd.mm.yyyy 11-3-2015 20-3-2015 27-3-2015 12-3-2015 12-3-2015 13-03-2015 6-3-2015 20-3-2015 
Date of sample collection day 4 dd.mm.yyyy 12-3-2015 21-3-2015 28-3-2015 13-3-2015 13-3-2015 14-03-2015 7-3-2015 21-3-2015 
Date of sample collection day 5 dd.mm.yyyy 13-3-2015 22-3-2015 29-3-2015 14-3-2015 14-3-2015 15-03-2015 8-3-2015 22-3-2015 
Date of sample collection day 6 dd.mm.yyyy 14-3-2015 23-3-2015 30-3-2015 15-3-2015 15-3-2015 16-03-2015 9-3-2015 23-3-2015 
Date of sample collection day 7 dd.mm.yyyy 15-3-2015 24-3-2015 31-3-2015 16-3-2015 16-3-2015 17-03-2015 10-3-2015 24-3-2015 
Total influent day 1 m3/24h 197493 234264 50228 148724 423110 333480 47740 157084 
Total influent day 2 m3/24h 204491 235442 49161 150936 403240 308279 45030 161005 
Total influent day 3 m3/24h 198950 234906 43728 147175 412310 277450 49530 161427 
Total influent day 4 m3/24h 197523 233096 38301 144840 402240 256766 46030 200010 
Total influent day 5 m3/24h 252682 230375 37243 145197 403020 250384 46900 243013 
Total influent day 6 m3/24h 220687 234774 37469 137793 422690 254570 45970 177167 
Total influent day 7 m3/24h 193194 359951 40476 137244 597470 252722 44580 160912 
Sampling mode -proportional time volume time volume volume volume volume volume 
Sampling interval m3 or min 15 min 1300 m3 15 min 2000 m3 3800 m3 1500 m3 400 m3 900 m3 
Sampling frequency day 1 min 15 8 15 19 13 6 12 8 
Sampling frequency day 2 min 15 8 15 19 14 7 13 8 
Sampling frequency day 3 min 15 8 15 20 13 8 12 8 
Sampling frequency day 4 min 15 8 15 20 14 8 13 6 
Sampling frequency day 5 min 15 8 15 20 14 9 12 5 
Sampling frequency day 6 min 15 8 15 21 13 8 13 7 
Sampling frequency day 7 min 15 5 15 21 9 9 13 8 
Average wastewater temperature day 1 °C n.a. n.a. 13.1 n.a. 17.5 7.8 13.5 14.7 
Average wastewater temperature day 2 °C n.a. n.a. 12.0 n.a. 17.6 8.0 n.a. 14.7 
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Average wastewater temperature day 3 °C n.a. n.a. 16.7 n.a. 17.6 8.2 n.a. 14.7 
Average wastewater temperature day 4 °C n.a. n.a. n.a. n.a. 17.7 8.1 14.1 14.1 
Average wastewater temperature day 5 °C n.a. n.a. n.a. n.a. 17.5 8.2 n.a. 12.6 
Average wastewater temperature day 6 °C n.a. n.a. 17.5 n.a. 17.2 8.5 13.0 14.2 
Average wastewater temperature day 7 °C n.a. n.a. 19.5 n.a. 16.0 8.7 n.a. 14.7 
pH in sample day 1 
 
n.a. n.a. 7.4 8.0 8.0 7.5 8.6 7.8 
pH in sample day 2 
 
n.a. n.a. 6.9 8.0 7.9 n.a. 8.3 8.1 
pH in sample day 3 
 
n.a. n.a. 7.6 8.2 7.7 n.a. 8.3 8.3 
pH in sample day 4 
 
n.a. n.a. n.a. 8.1 7.8 n.a. 8.0 8.0 
pH in sample day 5 
 
n.a. n.a. n.a. 8.0 7.7 n.a. 8.1 8.0 
pH in sample day 6 
 
n.a. n.a. 7.5 8.0 7.7 n.a. 8.3 8.1 
pH in sample day 7 
 
n.a. n.a. 7.7 8.1 7.6 7.4 8.1 8.0 
BOD5 day 1 mg/L n.a. n.a. 245 411 183 103 n.a. n.a. 
BOD5 day 2 mg/L n.a. n.a. 245 377 172 n.a. n.a. n.a. 
BOD5 day 3 mg/L n.a. n.a. 250 451 179 n.a. n.a. n.a. 
BOD5 day 4 mg/L n.a. n.a. n.a. 423 n.a. n.a. n.a. n.a. 
BOD5 day 5 mg/L n.a. n.a. n.a. 456 n.a. n.a. n.a. n.a. 
BOD5 day 6 mg/L n.a. n.a. 200 434 175 n.a. n.a. n.a. 
BOD5 day 7 mg/L n.a. n.a. 360 439 102 186 n.a. n.a. 
COD day 1 mg/L n.a. n.a. 516 909 372 273 530 n.a. 
COD day 2 mg/L n.a. n.a. 516 585 344 n.a. 811 n.a. 
COD day 3 mg/L n.a. n.a. 498 664 303 n.a. 530 n.a. 
COD day 4 mg/L n.a. n.a. n.a. 644 298 n.a. 568 n.a. 
COD day 5 mg/L n.a. n.a. n.a. 755 292 n.a. 598 n.a. 
COD day 6 mg/L n.a. n.a. 677 693 385 n.a. 648 n.a. 
COD day 7 mg/L n.a. n.a. 807 667 226 372 524 n.a. 
Ntot day 1 mg/L n.a. n.a. 47.5 64.4 31.0 n.a. n.a. n.a. 
Ntot day 2 mg/L n.a. n.a. n.a. 61.7 29.4 n.a. n.a. n.a. 
Ntot day 3 mg/L n.a. n.a. n.a. 57.8 29.9 n.a. n.a. n.a. 
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Ntot day 4 mg/L n.a. n.a. n.a. 66.1 n.a. n.a. n.a. n.a. 
Ntot day 5 mg/L n.a. n.a. n.a. 64.3 n.a. n.a. n.a. n.a. 
Ntot day 6 mg/L n.a. n.a. 76.0 63.2 31.6 n.a. n.a. n.a. 
Ntot day 7 mg/L n.a. n.a. n.a. 61.2 21.0 n.a. n.a. n.a. 
Ptot day 1 mg/L n.a. n.a. 7.4 9.7 3.6 3.5 8.9 n.a. 
Ptot day 2 mg/L n.a. n.a. n.a. 8.9 3.5 3.5 9.9 n.a. 
Ptot day 3 mg/L n.a. n.a. n.a. 8.7 3.5 3.5 10.3 n.a. 
Ptot day 4 mg/L n.a. n.a. n.a. 9.0 n.a. 3.5 9.2 n.a. 
Ptot day 5 mg/L n.a. n.a. n.a. 10.1 n.a. 3.5 9.7 n.a. 
Ptot day 6 mg/L n.a. n.a. 8.0 9.3 3.9 4.3 9.1 n.a. 
Ptot day 7 mg/L n.a. n.a. n.a. 9.5 2.4 4.3 9.7 n.a. 
NH4-N day 1 mg/L n.a. n.a. n.a. 44.0 n.a. 15.9 40.7 20.9 
NH4-N day 2 mg/L n.a. n.a. n.a. 41.0 n.a. n.a. 55.8 26.6 
NH4-N day 3 mg/L n.a. n.a. n.a. 41.0 n.a. n.a. 41.9 23.0 
NH4-N day 4 mg/L n.a. n.a. n.a. 45.0 n.a. n.a. 38.7 21.1 
NH4-N day 5 mg/L n.a. n.a. n.a. 44.0 n.a. n.a. 43.3 17.8 
NH4-N day 6 mg/L n.a. n.a. n.a. 42.0 n.a. n.a. 41.1 20.8 
NH4-N day 7 mg/L n.a. n.a. n.a. 41.0 n.a. 21.4 39.4 28.6 
n.a. not available  
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Table SI-2. Selected PDE5 inhibitors and LC-MS/MS parameters used for compounds 
identification. 
 CAS number 
Molecular 
formula 
Log 
Kow 
(*) 
[M+H]+ 
Product 
ions 
(m/z) 
Collision 
energy 
(V) 
S-Lens RT (min) 
Sildenafil 
(ILIS 1) 
171599-83-0 C22H30N6O4S 2.30 475.2 
58.2 (Q) 36 
118 10.5 
100.2 
(q1) 
28 
283.2 
(q2) 
36 
Desmethylsildenafil 
(ILIS 2) 
139755-82-1 C21H28N6O4S 2.09 461.1 
283.1 (Q) 35 
130 9.6 
311.1 (q) 29 
Desethylsildenafil 
(ILIS 1) 
139755-91-2 C20H28O4N6S 1.99 449.2 
283.1 (Q) 36 
138 9.4 
311.1 (q) 27 
Noracetildenafil 
(ILIS 1) 
949091-38-7 C24H32N6O3 n.a. 453.2 
97.1 (Q) 31 
148 9.2 
113.1 (q) 31 
Tadalafil 
(ILIS 1) 
171596-29-5 C22H19N3O4 0.04 390.0 
204.1 (Q) 57 
92 13.9 
268.1 (q) 14 
Aminotadalafil 
(ILIS 1) 
385769-84-6 C21H18N4O4 -1.20 391.0 
204.1 (Q) 56 
87 11.9 
262.1 (q) 31 
Chloropretadalafil 
(ILIS 1) 
171489-59-1 C22H19ClN2O5 2.58 427.1 
274.1 (Q) 31 
93 16.9 
135.0 (q) 19 
N-octyl nortadalafil 
(ILIS 1) 
1173706-35-8 C29H33N3O4 5.22 488.2 
366.2 (Q) 17 
120 17.8 
169.1 (q) 39 
Vardenafil 
(ILIS 1) 
224789-15-5 C23H33N6O4S 2.79 489.3 
151.1 (Q) 41 
159 9.6 
312.1 (q) 39 
N-desethylvardenafil 
(ILIS 1) 
448184-46-1 C21H28N6O4S 2.09 461.2 
151.1 (Q) 43 
143 9.6 
312.2 (q) 33 
ILIS 1 
Sildenafil-d8  
951385-68-5 C22H22D8N6O4S 2.30 483.3 
62.1 (Q) 37 
126 10.5 
108.3 (q) 29 
ILIS 2: 
Desmethylsildenafil-d8  
1185168-06-2 C21H20D8N6O4S 2.09 469.2 
283.1 (Q) 37 
160 10.7 
311.1 (q) 30 
n.a.: not available 
(*) Log Kow (KOWWIN program estimates)
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Table SI-3. Method performance: linearity, limits of detection and quantification, intraday and interday repeatability, procedural recovery and 
matrix effect. 
 linearity LOD LOQ  Intraday repeatability (RSD (%) , n=7) Interday repeatability (RSD (%), n=7, d=3) Procedural Recovery ± RSD (%) Matrix Effect ± RSD (%) 
  (r2) (ng/L) (ng/L) 20 ng/L 50 ng/L 100 ng/L 500 ng/L 20 ng/L 50 ng/L 100 ng/L 500 ng/L 20 ng/L 50 ng/L 100 ng/L 500 ng/L 20 ng/L 50 ng/L 100 ng/L 500 ng/L 
sildenafil 0.9997 1.8 6 16 10 5 5 24 9 10 9 93.1 ± 19.7 102.7 ± 10.4 100.1 ± 11.7 97.5 ± 14.7 241.9 ± 22.6 247.8 ± 15.9 82.3 ± 10.1 73.6 ± 12.2 
desmethylsildenafil 0.9999 5.4 18 27 15 7 12 25 24 8 9 99.9 ± 20.2 100.4 ± 16.9 99.9 ± 12.5 90.8 ± 21.1 406.6 ± 35.0 437.1 ± 34.7 116.8 ± 12.6 82.0 ± 21.3 
desethylsildenafil 0.9997 0.5 1.6 18 11 10 4 33 18 9 8 97.2 ± 22.1 100.7 ± 10.4 102.3 ± 11.4 93.2 ± 19.0 393.4 ± 30.9 549.0 ± 17.1 156.8 ± 14.7 99.8 ± 13.3 
noracetil 0.9990 6 20 31 13 5 6 36 23 9 6 94.8 ± 57.7 102.7 ± 17.1 104.4 ± 13.9 99.0 ± 15.7 298.6 ± 85.3 216.1 ± 33.6 70.5 ± 51.0 46.7 ± 34.0 
tadalafil 0.9998 2.3 7.5 10 11 11 7 13 13 13 11 89.3 ± 21.5 96.5 ± 7.8 96.0 ± 8.6 97.7 ± 12.7 246.6 ± 23.6 270.1 ± 14.2 84.0 ± 10.3 72.2 ± 12.5 
aminotadalafil 0.9995 1.8 6 8 11 11 8 14 16 11 11 91.3 ± 16.5 100.9 ± 8.6 97.5 ± 8.8 98.2 ± 13.9 217.5 ± 15.7 251.0 ± 15.4 77.8 ± 10.8 69.1 ± 13.6 
chloropretadalafil 0.9993 4 13.3 6 8 9 8 12 15 8 10 93.4 ± 15.4 87.2 ± 8.4 91.7 ± 10.2 92.4 ± 11.5 195.0 ± 20.6 243.8 ± 14.2 73.1 ± 10.2 64.9 ± 13.6 
n-octylnortadalafil 0.9999 30 100 11 15 10 10 20 27 26 16 - - 16.4 ± 20.5 27.4 ± 36.8 163.1 ± 19.3 234.0 ± 24.1 77.4 ± 18.8 75.3 ± 10.9 
vardenafil 0.9998 7.2 24 17 18 9 5 22 20 14 7 92.2 ± 23.6 101.3 ± 12.2 102.1 ± 12.5 96.6 ± 12.1 320.5 ± 32.2 322.7 ± 24.9 96.5 ± 17.2 83.4 ± 12.3 
n-desethylvardenafil 0.9998 9 30 26 16 9 8 37 30 15 13 95.4 ± 25.0 96.5 ± 14.4 98.9 ± 13.0 97.0 ± 16.7 607.0 ± 26.9 616.0 ± 26.0 152.1 ± 14.7 125.8 ± 13.0 
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Table SI-4. Amount of API prescribed in 2015, expressed in mg year-1. 
Country 
Prescribed mg year-1  
Sildenafil a Tadalafil Vardenafil 
Belgium 3,23  107 b 8,53  105 n.a. 
England 1,18  109 9,12  107 1,26  107 
Italy 6,66  108 1,33  108 n.a. 
the Netherlands 1,17  108 1,57  107 1,60  106 
Norway 9,75  107 2,20  107 3,38  106 
a total sildenafil 
b Estimated from the ED/VA ratio observed in the Netherlands 
n.a.: not available 
 
 
 
 
Figure SI-1. Chromatogram from a standard mixture of the selected PDE5 at 50 ng L-1 
concentration level. 
 
